The clinical research of the application of Micra leadless pacemaker system
Objective To explore the safety and effectiveness of the clinical application of the Micra leadless pace-maker(LP)system.Method A total of 41 patients with arrhythmia who were hospitalized at Nanjing Drum Tower Hospital from January 2020 to December 2022 and had indications for LP system were selected consecutively.Among them,there were 21 cases of LP implantation after removing the electrode wire because of infection(LP re-implantation group)and 20 cases of first time implantation of LP(LP first time implantation group).Compare and analyze the surgical time,release frequency,X-ray exposure time,pacing parameters,and complications between the two groups.Follow up the pacing parameters of two groups at 1,3,6,and 12 months after LP implantation.Result LP implantation of Micra system were selected in all patients and the implant site was the mid to high level of septum.Patients in LP reimplantion group included 15 males(71.4％)with an average age of(72.5±19.1)years.Patients in LP first time implantation group included 12 males(60％)with an average age of(60.8±8.4)years.There were no statistically significant differences in surgical time,the proportion of release≤2 times,X-ray expo-sure time,pacing threshold,perception,impedance between the two groups(P＞0.05).No surgical and device re-lated complications occurred.There were no statistically significant differences in pacing threshold,perception,and impedance between the two groups at 1 month,3 month,6 month,12 month of follow-up after LP implantation(P＞0.05).Conclusion LP is a safe and feasible clinical choice not only for the first time implantation patients but also for the reimplantation patients after removal infected pacemaker.
NETL
NSTL
万方数据
